Front Page News
Cure SMA Database Findings Published in the Journal of Neuromuscular Diseases
An important goal at Cure SMA is to collect data to better understand the SMA patient population, and then to report this data back to […]
Read More ›Novartis Agrees to Acquire AveXis
AveXis, Inc. and Novartis announced today that they have entered into an agreement and plan of merger. Novartis will acquire AveXis in a transaction unanimously […]
Read More ›SMA Newborn Screening Guidelines Published in Journal of Neuromuscular Diseases
The recent decision of the federal Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) to recommend SMA for addition to the RUSP, as […]
Read More ›Community Spotlight: Nathan Yates
Growing up in Virginia, Nathan Yates always had a vision for his future. From an early age, he became interested in finance, and as a […]
Read More ›Cure SMA Welcomes Back AveXis as a 2018 National Premier Partner
Cure SMA is excited to announce that AveXis is returning as a National Premier Partner for 2018. As part of their partnership, AveXis is generously […]
Read More ›Cure SMA Awards $150,000 Grant to Brunhilde Wirth, PhD, Institute of Cologne, Germany
Cure SMA has awarded a $150,000 research grant to Brunhilde Wirth, PhD, at Institute of Cologne, Germany, for her project, “Study of combinatorial therapy based […]
Read More ›Cure SMA Awards $50,000 Grant to Rashmi Kothary, PhD, University of Ottawa
Cure SMA has awarded a $50,000 research grant to Rashmi Kothary, PhD, at the University of Ottawa, for his project, ” The shifting landscape of […]
Read More ›Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015 for the Treatment of Patients with SMA
Scholar Rock today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead antibody product candidate, SRK-015, […]
Read More ›Cure SMA Awards $150,000 Grant to Robin Parks, PhD, University of Ottawa
Cure SMA has awarded a $150,000 research grant to Robin Parks, PhD, at the University of Ottawa, for his project, “Serum-derived exosomes as a biomarker […]
Read More ›Cure SMA Welcomes Back Biogen as a National Premier Partner for 2018
Cure SMA is thrilled to welcome Biogen back as a National Premier Partner for 2018. As a part of their partnership, Biogen will be sponsoring […]
Read More ›